TIDMAG99 TIDMGSK
RNS Number : 5044G
GlaxoSmithKline Capital PLC
15 November 2022
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT
QUALIFIES OR MAY QUALIFY AS INSIDE INFORMATION WITHIN THE MEANING
OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT
FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 (EUWA).
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO
ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED
STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING
PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE
ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED
STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES)
OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT
IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT
GlaxoSmithKline Capital plc announces results of tender offers
for its outstanding Notes ( the Notes and each a Series) listed in
the table below, in each case guaranteed by GSK plc (GSK)
15 November 2022.
GlaxoSmithKline Capital plc (the Offeror) announces today the
results of its invitation to holders of its outstanding Notes to
tender their Notes for purchase by the Offeror for cash (each, an
Offer and together, the Offers). The Offeror announced the
indicative results of the Offers earlier today.
The Offers were announced on 8 November 2022 and were made on
terms and subject to the conditions contained in the tender offer
memorandum dated 8 November 2022 (the Tender Offer Memorandum).
Capitalised terms used in this announcement but not defined have
the meanings given to them in the Tender Offer Memorandum.
Results of the Offers
The Offeror announces that it will accept for purchase in cash
an aggregate nominal amount of the Notes validly tendered pursuant
to the Offers equal to GBP1,593,679,000. The final results of the
Offers are as follows:
Notes Description of ISIN / Common Aggregate Series Scaling Purchase Purchase Accrued
the Notes Code nominal amount Acceptance Factor Yield (per Price (per Interest
of Notes Amount (per cent.) cent.) Payment (per
tendered cent.) GBP1,000)
------- ------------------ -------------- ---------------- ---------------- ----------- ----------- ----------- ---------------
GBP600,000,000
3.375 per cent.
2027 Notes due 20 XS0866588527 Not
Notes December 2027 / 086658852 GBP292,230,000 GBP292,230,000 Applicable 4.388 95.460 GBP30.70
GBP1,000,000,000
5.250 per cent.
2033 Notes due 19 XS0140516864
Notes December 2033 / 014051686 GBP734,199,000 GBP350,051,000 47.700 4.238 108.875 GBP21.66
2039 GBP700,000,000 XS0350820931 GBP409,561,000 GBP0 0.000 Not Not Not Applicable
Notes 6.375 per cent. / 035082093 Applicable Applicable
Notes due 9 March
2039
GBP1,000,000,000
5.250 per cent.
2042 Notes due 10 XS0294624373 Not
Notes April 2042 / 029462437 GBP522,184,000 GBP522,184,000 Applicable 4.495 109.604 GBP31.79
GBP800,000,000
4.250 per cent.
2045 Notes due 18 XS0866596975 Not
Notes December 2045 / 086659697 GBP429,214,000 GBP429,214,000 Applicable 4.415 97.639 GBP38.89
General
The Settlement Date in respect of the Notes accepted for
purchase pursuant to the Offers is expected to be 17 November
2022.
Following the Settlement Date, GBP307,770,000 in aggregate
nominal amount of the 2027 Notes will remain outstanding,
GBP649,949,000 in aggregate nominal amount of the 2033 Notes will
remain outstanding, GBP700,000,000 in aggregate nominal amount of
the 2039 Notes will remain outstanding, GBP477,816,000 in aggregate
nominal amount of the 2042 Notes will remain outstanding and
GBP370,786,000 in aggregate nominal amount of the 2045 Notes will
remain outstanding.
The Dealer Managers (in respect of the Offers as made to
Relevant Noteholders)
BNP Paribas
16, boulevard des Italiens
75009 Paris
France
Telephone: +33 1 55 77 78 94
Attention: Liability Management Group
Email: liability.management@bnpparibas.com
J.P. Morgan Securities plc
25 Bank Street
Canary Wharf
London E14 5JP
United Kingdom
Telephone: +44 207 134 2468
Attention: EMEA Liability Management Group
Email: liability_management_EMEA@jpmorgan.com
The Offeror
GlaxoSmithKline Capital plc
980 Great West Road
Brentford
Middlesex TW8 9GS
United Kingdom
Email: company.secretary@gsk.com
The Tender Agent
Kroll Issuer Services Limited
The Shard
32 London Bridge Street
London SE1 9SG
United Kingdom
Telephone: +44 20 7704 0880
Attention: David Shilson
Email: gsk@is.kroll.com
Website: https://deals.is.kroll.com/gsk
This announcement contains information that qualifies or may
qualify as inside information. The person responsible for arranging
the release of this announcement on behalf of GlaxoSmithKline
Capital plc is Victoria Whyte, Company Secretary.
DISCLAIMER This announcement must be read in conjunction with
the Tender Offer Memorandum. No offer or invitation to acquire any
securities is being made pursuant to this announcement. The
distribution of this announcement and the Tender Offer Memorandum
in certain jurisdictions may be restricted by law. Persons into
whose possession this announcement and/or the Tender Offer
Memorandum comes are required by each of the Offeror, GSK, the
Dealer Managers and the Tender Agent to inform themselves about,
and to observe, any such restrictions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TENKZMMMKKZGZZM
(END) Dow Jones Newswires
November 15, 2022 10:53 ET (15:53 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
